Paul Modafferi
Family · Tallahassee, FLNPI 1760880082
Payments from drug & device makers
Across 668 payments — averaging $18.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$1K
- Amgen$1K
- Lilly USA, LLC$1K
- Bayer$978
- Pfizer$954
- plus $5K from 31 others
What the payments were for
- Food & beverage$12,088100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,588 |
| AstraZeneca | 52 | $1,339 |
| Amgen | 53 | $1,244 |
| Lilly USA, LLC | 74 | $1,078 |
| Bayer | 74 | $978 |
| Pfizer | 49 | $954 |
| AbbVie | 72 | $832 |
| Boehringer Ingelheim | 23 | $418 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $414 |
| GSK | 28 | $389 |
| Astellas Pharma US Inc | 20 | $340 |
| Sanofi-aventis U.S. LLC | 15 | $310 |
| Phathom Pharmaceuticals, Inc. | 5 | $235 |
| Abbott | 10 | $216 |
| Novartis | 11 | $193 |
| Merck | 10 | $147 |
| Exact Sciences | 8 | $144 |
| Dexcom, Inc. | 8 | $139 |
| Almatica Pharma LLC | 8 | $138 |
| Biohaven Pharmaceuticals, Inc. | 7 | $116 |
| Johnson & Johnson | 6 | $114 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $114 |
| Idorsia Pharmaceuticals US Inc | 5 | $93 |
| UCB, Inc. | 3 | $89 |
| Corcept Therapeutics | 4 | $81 |
| Kowa Pharmaceuticals America, Inc. | 4 | $64 |
| Amarin Pharma, Inc. | 3 | $62 |
| Sumitomo Pharma America, Inc. | 1 | $60 |
| Esperion Therapeutics, Inc. | 2 | $36 |
| IBSA Pharma Inc. | 2 | $34 |
| Medtronic | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Biogen | 1 | $20 |
| Inogen, Inc. | 1 | $17 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $16 |
| Azurity Pharmaceuticals, Inc. | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,088 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 116 | $143,288 |
| JanuviaSitagliptin Phosphate | 73 | $92,822 |
| TrulicityDulaglutide | 59 | $91,883 |
| JardianceEmpagliflozin | 56 | $87,370 |
| EliquisApixaban | 83 | $77,775 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 76 | $72,710 |
| MounjaroTirzepatide | 46 | $58,196 |
| OzempicSemaglutide | 32 | $50,134 |
| XareltoRivaroxaban | 40 | $40,666 |
| MyrbetriqMirabegron | 30 | $38,904 |
| Nurtec OdtRimegepant Sulfate | 29 | $33,448 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $24,989 |
| Tresiba Flextouch U-100Insulin Degludec | 23 | $24,670 |
| EntrestoSacubitril/Valsartan | 14 | $22,614 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $21,369 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy | $418 | $183,435157 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,339 | $165,604156 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $1,078 | $150,079105 claims |
| PfizerEliquis, Nurtec Odt | $954 | $111,223112 claims |
| MerckJanuvia, Janumet Xr | $147 | $102,51487 claims |
| Novo NordiskOzempic | $1,588 | $50,13432 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $389 | $46,83750 claims |
| Johnson & JohnsonXarelto | $114 | $40,66640 claims |
| Astellas Pharma US IncMyrbetriq | $340 | $38,90430 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $310 | $24,98917 claims |
| NovartisEntresto | $193 | $22,61414 claims |
| BayerKerendia | $978 | $17,82619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Tallahassee
- Kathleen WilsonTallahassee$154K
- Brittany YatesTallahassee$73K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.